PMC3658243_01
Monthly oscillation of absolute eosinophil counts (AEC) in the patient. Peaks of AEC are seen to be significantly reduced from 2005 to 2007 (A), and from 2008 to 2010 (B). . Note: Numbers in the abscissa indicate months from January to December.
imcrj-4-079f1.jpg
PMC3658243_01_imcrj-4-079f1.jpg
f1-imcrj-4-079
This revealed episodes of abundant eosinophilia (AEC >10,000/muL) two to three times a year, one in early spring (February-March), another in fall (September-October) and another in between (June) in two of the 3 years from 2005 to 2007 (Figure 1A). A was proven beneficial in the treatment of HES and the suplatast tosilate, the Th2 cytokine inhibitor, was reported effective for a patient with hypereosinophilia with a high level of serum IL-5 as well as for a patient with eosinophilic gastroenteritis associated with elevated serum IL-5 and sIL-2R, we employed a combination of oral suplatast tosilate (300 mg/day) combined with cyclosporine A (150 mg/day) and prednisolone (10-15 mg/day) over the past 6 years. As seen in Figure 1, peak heights of AEC reduced from 2005 to 2007 (Figure 1A), and further reduced yearly to 2010 in association with reduced incidence of the episodes (Figure 1B).
Correlation between absolute neutrophil counts (AEC) and serum IgM levels.
imcrj-4-079f2.jpg
PMC3658243_01_imcrj-4-079f2.jpg
f2-imcrj-4-079
Among various biological markers, soluble IL-2R (r = 0.857, P < 0.001) and serum IgM (r = 0.685, P < 0.0025) values were closely associated with this eosinophilic oscillation (Figure 2); however, none of hemoglobin, platelet counts, IgG, or IgA levels were correlated with the oscillation in eosinophil levels.